ERBB2 and breast carcinoma: Various concentrations of either trastuzumab or human normal IgG ranging from 0 to 100 μg/ml were added to cultures of HER2-positive SCLC and breast cancer cells, and the antiproliferative effects were assessed by CCK-8, a tetrazolium reagent, assay.